Publication date: Jul 12, 2024
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to
| Concepts | Keywords |
|---|---|
| Investigator | Influenza |
| Nonchildbearing | mRNA-1083 |
| Vaccine | SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Influenza |
| disease | VO | vaccine |
| disease | VO | injection |
| disease | VO | protocol |
| disease | MESH | complications |
| disease | IDO | history |
| disease | IDO | acquired immunodeficiency |
| disease | MESH | infections |
| disease | MESH | anaphylaxis |
| disease | MESH | hypersensitivity |
| disease | IDO | intervention |
| drug | DRUGBANK | Dihydrotachysterol |
| drug | DRUGBANK | Prednisone |
| disease | VO | time |
| drug | DRUGBANK | Infliximab |
| disease | VO | Optaflu |
| disease | MESH | coronavirus disease 2019 |
| disease | VO | combination vaccine |
Original Article
(Visited 3 times, 1 visits today)